A TRPC3 blocker, Pyr3, prevents stent-induced arterial remodeling by unknown
MEETING ABSTRACT Open Access
A TRPC3 blocker, Pyr3, prevents stent-induced
arterial remodeling
Sarah König1, Sara Browne1, Heinrich Mächler2, Gerald Höfler3, C Oliver Kappe4, Toma N Glasnov4, Marlen Braune5,
Eric Wittchow5, Klaus Groschner1*
From 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the
Croatian, Serbian and Slovenian Pharmacological Societies.
Graz, Austria. 20-21 September 2012
Background
TRPC-mediated Ca2+ entry has been implicated in the
control of smooth muscle proliferation and might repre-
sent a pivotal mechanism underlying in-stent restenosis.
As we have observed significant expression of TRPC3 in
human smooth muscle from coronary arteries as well as
from aorta, we tested the efficiency of a recently discov-
ered TRPC3-selective Ca2+ entry blocker, Pyr3 (10 µM) to
prevent vascular smooth muscle proliferation and stent
implantation-induced hyperplasia of human aorta.
Methods and results
The effect of Pyr3 on proliferation was measured by detec-
tion of BrDU incorporation and PCNA expression in
human coronary smooth muscle and microvascular
endothelium, which displays significantly smaller expres-
sion levels of TRPC as compared to smooth muscle. Pyr3
inhibited smooth muscle proliferation with an IC50 of
about 3 µM but lacked detectable effects on endothelial
proliferation. Measurements of ATP-induced Ca2+ signals
revealed that Pyr3 suppressed agonist-induced Ca2+ entry
more effectively in vascular smooth muscle as compared
to endothelial cells. Inhibitory effects of Pyr3 on stent
implantation-induced arterial injury were tested using a
novel in vitro model of in-stent hyperplasia in human
arteries based on organ-typical culture of human aortic
constructs. Pyr3 (10 µM) effectively prevented increases in
tissue levels of proliferation markers (PCNA and Ki67) at
2 weeks after stent implantation into human aortae. Simi-
larly, proliferation markers were significantly suppressed
when implanting a Pyr3-releasing stent prototype as com-
pared to a bare metal stent control.
Conclusions
Our results suggest TRPC3 as a potential target for phar-
macological control of smooth muscle proliferation.
Selective inhibition of TRPC Ca2+ entry channels in vas-
cular smooth muscle is suggested as a promising strategy
for in-stent restenosis prevention.
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